Key statistics
On Friday, Jazz Pharmaceuticals PLC (J7Z:FRA) closed at 127.20, -5.04% below its 52-week high of 133.95, set on Feb 14, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 129.25 |
---|---|
High | 133.95 |
Low | 127.00 |
Bid | 127.55 |
Offer | 127.80 |
Previous close | 130.70 |
Average volume | 140.30 |
---|---|
Shares outstanding | 60.45m |
Free float | 58.68m |
P/E (TTM) | 16.94 |
Market cap | 7.27bn USD |
EPS (TTM) | 7.10 USD |
Data delayed at least 15 minutes, as of Feb 14 2025 20:55 GMT.
More ▼
Press releases
- Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
- Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals Announces CEO Succession Plan
- Jazz Pharmaceuticals Announces CEO Succession Plan
- Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
- Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
- Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
- Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
More ▼